Stay updated with breaking news from Todd Binder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEUVOGEN Appoints Biotechnology Veteran, Mark Backer, PhD as Head of Technical Operations - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ -- NEUVOGEN, an immunoncology company, announced today that Mark Backer, PhD has joined the company as Head of Technical Operations, and will be...
/PRNewswire/ -- NEUVOGEN, an immunoncology company, is pleased to announce the appointment of George Montgomery as Chief Financial Officer. He will oversee...
/PRNewswire/ -- NEUVOGEN, an immunoncology company, is pleased to announce the appointment of George Montgomery as Chief Financial Officer. He will oversee...
ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology News provided by Share this article Share this article LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ -- ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement. Under the terms of the agreement, ImaginAb will work with NEUVOGEN to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents into their...